   |
|
David Pieroni, Managing Director of Automation Quality Solutions (AQS) |
| This month, GBI sits down with Dr. Sean Hu, Chairman and CEO of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry. |
|
|
Dr. Sean Hu, Chairman and CEO of Beike Biotechnology |
| This month, GBI sits down with Dr. Sean Hu, Chairman and CEO of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry. |
|
|
Mark Cohen and Tony Chen of Jones Day |
| In this interview IP experts Mark Cohen and Tony Chen shared their deep cumulative experiences from both the policy and practice perspective. In addition to broad patent and trademark issues, Mark and Tony explained the inventor's rights portions of the new patent law, explain the use of China to avoid platform technology patents, and discussed the outlook and forces for change in China's IP regime. |
|
|
Philip Xiao, CDO of Profex Inc |
| In this interview, Philip Xiao, the co-founder and CDO of Profex Inc, discusses such topics as Profex's struggle to grow from a small startup into a major player in China's dermatology market, the unique challenges facing Profex, anticipated effects of the new medical reform, and the company's future plans. |
|
|
Victor Shi, President of Qiagen Asia |
| In this interview, Victor enlightens us on Qiagen's China products and services, the possible impact of the nation's healthcare reform on the molecular diagnostics sector, and the competitive landscape in Qiagen's business segments. Victor also addresses the company’s strategic plan for Asia as well as its past China acquisitions and the challenges associated with integrating those businesses. |
|
|
Sheldon Dorenfest, CEO of the Dorenfest Group |
| Interview with Sheldon Dorenfest, CEO of the Dorenfest Group, an investment and consulting firm focused on health care systems improvement. In this interview, Sheldon, an internationally recognized authority on healthcare I.T., expands on the positives and negatives of the Chinese healthcare system, the status of I.T. in healthcare institutions, and the I.T. resources currently needed by the nation’s physicians. Sheldon also discusses the entry of multinational I.T. providers, such as IBM and Microsoft, to the H.I.T. market and regulatory roadblocks to future progression of the sector. |
|
|
Ben Avancena, General Manager of Johnson & Johnson Medical (China) |
| Interview with Ben Avancena, General Manager of Johnson & Johnson Medical (China) and international vice president for Johnson & Johnson's medical diagnostics division. In this interview, Ben discusses the highlights and challenges of being the GM of a multinational medical device company in China, the impact of the new healthcare reforms on the medical device and diagnostics sector, and strategies for multinational and domestic medical device companies going forward in China. |
|
|
Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch |
| Interview with Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch. Carl analyzes China’s deal landscape for healthcare, the current investor environment, M&A appetites of both multinationals and domestics, and gives his observations of changes in the sector that have occurred over the past 12 to 18 months. |
|
|
Arthur C. Mok, partner at Hogan & Hartson Shanghai |
| Interview with Arthur C. Mok, partner at Hogan & Hartson's Shanghai office. In this interview, Arthur shares his insights on the current deal environment in China's healthcare industry. He discusses the impact of the global economic crisis on investment and important covenants in acquisition and licensing deals in China. |
|
|
Jonathan Seah, CEO of ParkwayHealth China |
| Interview with Dr. Jonathan Seah, former CEO of ParkwayHealth China. ParkwayHealth is one of the largest providers of private healthcare in Asia and China. In this interview, Jonathan discusses Parkway's strategy and approach in the mainland; the impact of the new medical reforms; and the past, present, and future of private healthcare in China. He also shares his plans for his latest venture. |
|
|
Reto Rietman, General Manager of Rxmidas |
| In this interview, Reto outlines his experience with Schwarz Pharma, his drive to create and expand RxMidas, and the key role of product sourcing strategies in to specialty pharmaceutical companies. Reto also touches on medical reform, his experience with distribution, the company’s focus on CNS and cardiovascular disease, and his vision for the company. |
|
|
Eric Zwisler, China Regional Director of Zuellig Pharma |
| In this interview Eric reflects on his 20 year experience in China, the development of the distribution industry and Zuellig's special role in the value chain. Eric shares his thoughts on M&A, consolidation, vertical integration, and the future of distribution in China's rapidly changing landscape. |
|
|
Dr. Allan Liu, Director of Business Development for Fosun Pharma |
| Interview with Dr. Allan Liu, Director of Business Development for Fosun Pharma, a major publicly listed domestic pharmaceutical company with business lines spanning therapeutics, diagnostics, and retail pharmacy. In this interview Allan discusses how Fosun uncovers business opportunities, and the company's areas of interest for licensing. He also gives an overview of the challenges facing the domestic pharmaceutical industry, including the struggle to develop in-house innovative R&D capabilities. |
|
|
Liu YuWen, General Manager of Suzhou BioBay |
| In this interview, YuWen discusses the progress BioBay has made in attracting companies, the status of its venture fund, the competitive landscape for biotech zones, and the challenges such zones face in developing the industry. She highlighted the park’s progresses and how she measures success. |
|
|
David Preston, former China General Manager of Sanofi-aventis |
| In this interview, Dave provided practical and strategic advice to pharmaceutical companies, especially those focused on China’s growing cancer market. He highlighted execution, pricing, and reimbursement issues and illuminated the importance of key hospitals and biologics. |
|
|
Mark Engel, CEO of Excel Pharmastudies, on clinical trials in China |
| In this interview, Mark discusses how he founded and grew Excel Pharmastudies into one of the leading CRO's in China. Mark also addressed opportunities and challenges for big pharma and biotech looking to conduct clinical trials in China. He specifically touches on chemical vs. biologic products, and the rapidly changing competitive landscape for clinical trials providers in China. |
|
|
Interview with Samantha Du, CEO of Hutchison Medipharma |
| Hutchison Medipharma is Shanghai-based pioneer in new drug discovery. In this interview, Samantha discusses the genesis of Medipharma, the company's leading products, progress in clinical trials, high profile deals with Lilly and others, and the current corporate structure. Samantha also elaborates on the company's patent estate and how Medipharma protects its small molecule, mixture, and extract candidates. |
|
|
Interview with Peter Zhang, CEO of GenePharma |
| This month GBI talked with Peter Zhang, CEO of GenePharma. GenePharma is a leading company in China's RNA industry. Peter touched the process of starting a biotech in China, challenges in financing and reaching overseas markets, and the state of China's RNA research. He also explained the reasons for the company’s move to Suzhou’s nascent BioBay from Shanghai's ZhangJiang high technology park. |
|
|
Interview with XianPing Lu, co-founder and president of Chipscreen Biosciences |
| This month GBI talked XianPing Lu, co-founder and president of Chipscreen Biosciences. Based in Shenzhen, Chipscreen is one of China's true drug discovery pioneers, having developed a platform technology and successfully driving several drug candidates into preclinical and clinical testing. In this interview, Dr. Lu discusses the founding of the company, its expanding pipeline, and the value of partnering with multinationals. He also touches on Chipscreen's plans for an IPO on China’s nascent NASDAQ-like board and strategy for commercialization of its late stage candidates. |
|
|
Interview with Jing Lou, CEO of 3SBio |
| This month, GBI sat down with Jing Lou, the CEO of 3SBio, a Chinese biopharmaceutical company that conducted an IPO on NASDAQ in February of 2007. In this interview, Dr. Lou discussed the company's leading product, a generic EPO, and the status of its other products and candidates. Dr. Lou discussed his plans for 3SBio's IPO cash, the impact of recent regulatory changes on the company's market share and prospects, and expanded on the potential for generic biologics in the European and United States markets. |
|
|
James Wen, CEO of SynCores, on chemical synthesis |
| James Wen, CEO of
SynCores, an emerging chemical synthesis service
provider, discusses his views on industry growth
in China, the evolution of the R&D services
business model, the impact of rising wages and
RMB pressure, and how to move from success based
projects to an FTE model. |
|
|
Vaccines
in China - Patrice Bonzom - China GM, Crucell |
| Patrice Bonzom, General Manager of Crucell in China, discusses China's vaccine industry. Covered in this interview is Crucell's growing presence, thoughts on the market for subsidized and unsubsidized vaccines, the potential of the influenza vaccine market, China's pandemic preparations, and multinationals' options for domestic manufacturing. |
|
|
Life
as a GM of Big Pharma in China |
| Kabir Nath, President of Bristol Myers Squibb in China, expands upon the roles of a GM of a multinational pharma in China and discusses BMS's success with Baraclude. Kabir also shares his thoughts on China's pricing process and discusses big pharma's growth constraints in China's rapidly expanding pharmaceutical market. |
|
|
Starting a Specialty Pharmaceutical Company in China |
| In this interview, Mark Lotter, founder and CEO of NovaMed, shares his experience transitioning from big pharma to a start-up, specialty pharmaceutical company in China. Mark addresses challenges facing pharmaceutical companies, including differences between sales and marketing strategies in China versus Western markets, and discusses the overall outlook of China's evolving market. |
|
|
PE and VC in China's Life Science Industry Part I |
| In this interview,
Arthur covers a lot of ground, hitting venture
capital, private equity, and entrepreneurialism
in China's healthcare and life science industries.
Arthur's experience ranges across a number of
deal types, from early to late stage, and public
offerings. |
|
| PE
and VC in China's Life Science Industry Part II |
| In this interview,
Arthur covers a lot of ground, hitting venture
capital, private equity, and entrepreneurialism
in China's healthcare and life science industries.
Arthur's experience ranges across a number of
deal types, from early to late stage, and public
offerings. |
|
| IP
in China Tony's Top 10 |
| In this interview,
Tony expands upon China's intellectual property
landscape, especially related to biotechnology
and pharmaceuticals. He addresses both systematic
challenges and practical considerations for multinationals,
investors, and China's domestic enterprises. |
|
| IP
in China ᾿Tony Addresses Common IP Questions |
| In this interview,
Tony expands upon China's intellectual property
landscape, especially related to biotechnology
and pharmaceuticals. He addresses both systematic
challenges and practical considerations for multinationals,
investors, and China's domestic enterprises. |
|
| |